Stocky turns companies like Novonesis Novozymes B into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. NSISBC.XD scores 29/100 overall, with weak Growth (35.6) and Value (34) Compounder signals indicating neither compelling earnings expansion nor valuation margin of safety. Leadership Alignment at 45/100 suggests misalignment between insiders and shareholders, raising governance concerns. Though the Vulnerability Index shows no acute structural risks, the combined weakness across growth, value, and management execution does not justify an investment thesis.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Novonesis Novozymes B:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 29/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Novonesis Novozymes B (NSISBC.XD) at 29/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. NSISBC.XD scores 29/100 overall, with weak Growth (35.6) and Value (34) Compounder signals indicating neither compelling earnings expansion nor valuation margin of safety. Leadership Alignment at 45/100 suggests misalignment between
NSISBC.XD's current Stocky Verdict is 29/100, placing it in the "Avoid" band. This composite combines a 36/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Novonesis Novozymes B yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Novonesis Novozymes B scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Novonesis Novozymes B's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Novonesis Novozymes B.
Sign up free and unlock the full analysis on NSISBC.XD — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for NSISBC.XD in the app.
